Table 3.
Correlations of SII and clinicopathological characteristics in patients with bladder cancer.
| Characteristics | No. of studies | No. of patients | Effects model | OR (95% CI) | p | Heterogeneity | |
|---|---|---|---|---|---|---|---|
| I2 (%) | p | ||||||
| Age (old vs. young) | |||||||
| Binary variables | 3 | 5,689 | Random | 1.36 (1.00, 1.85) | 0.439 | 70.2 | 0.035 |
| Sex (male vs. female) | 6 | 6,431 | Random | 0.97 (0.75, 1.24) | 0.780 | 54.0 | 0.054 |
| Concomitant CIS (yes vs. no) | 4 | 6,070 | Random | 1.23 (0.85, 1.79) | 0.269 | 58.3 | 0.066 |
| LNI (yes vs. no) | 2 | 4,572 | Random | 1.30 (1.13, 1.48) | 0.0 | 0.0 | 0.913 |
| LVI (yes vs. no) | 2 | 4,722 | Random | 1.80 (0.89, 3.68) | 0.107 | 73.2 | 0.053 |
| Tumor size (≥3 cm vs. <3 cm) | 4 | 1,859 | Random | 1.87 (1.07, 3.25) | 0.027 | 79.4 | 0.002 |
| Tumor number (unifocal vs. multifocal) | 3 | 1,720 | Random | 0.77 (0.53, 1.10) | 0.146 | 56.0 | 0.103 |
| Tumor differentiation (poor vs. well) | 2 | 603 | Random | 1.98 (1.20, 2.29) | 0.008 | 33.8 | 0.219 |
| Tumor stage | |||||||
| MIBC (≥T3 vs. < T3) | 3 | 4,711 | Random | 1.62 (1.44, 1.83) | 0.0 | 0.0 | 0.502 |
| NMIBC (T1 vs. < Tis-Ta) | 3 | 1,719 | Random | 1.48 (0.77, 2.87) | 0.243 | 81.4 | 0.005 |
SII, systemic immune-inflammation index; CIS, carcinoma in situ; LNI, lymph node involvement; LVI, lymphovascular invasion; MIBC, muscle-invasive bladder cancer; NMIBC, non-muscle-invasive bladder cancer; OR, odds ratio; CI, confidence interval.